Fungorin 1% is commonly used to help with skin infections caused by various species of fungi and yeast. This topical treatment is applied in addressing conditions associated with inflammatory or irritative processes, offering supportive relief when symptoms interfere with routine activities.

The medication may assist with the topical management of dermal infections, often referred to as dermatomycoses. These conditions characterized by periods of heightened symptoms include Tinea infections, such as tinea corporis (ringworm), tinea cruris (jock itch), and tinea pedis (athlete's foot). The medication may also be relevant for easing symptoms linked to cutaneous candidiasis (skin yeast infections). This application is generally used during phases when symptoms become more noticeable or temporarily overwhelming.

The cream is commonly used to help with symptoms related to physical discomfort, like itching, burning, and redness. It contributes to easing the overall symptom load and helps improve day-to-day comfort during symptomatic periods. The product assists with maintaining functional stability when symptoms interfere with routine activities.

Quick Fact: Relief for Physical Discomfort

Regulatory References

1. MedlinePlus Drug Information

The eligibility profile for Fungorin 1% (Terbinafine 1% Cream) is defined by regulatory bodies based on age, physiological status, and known allergies. This information is derived strictly from official government labeling, such as the Summary of Product Characteristics (SmPC) and FDA prescribing information.

Contraindicated and Restricted Use

Eligibility for Special Populations

Interactions with other medicines and products

Regulatory documentation establishes that Fungorin 1% (Terbinafine Hydrochloride 1% Cream) has a low potential for systemic drug-drug interactions. This profile is defined by its pharmacokinetic behavior following topical administration, which is the sole basis for its interaction profile.

Interaction Scope

The most significant factor is the very low systemic exposure. Official regulatory labels state that less than 5% of the administered dose is absorbed into the bloodstream after topical application. This minimal absorption is insufficient to cause clinically significant systemic interactions.

The entire interaction structure is defined by the absence of systemic effect. The official statements confirm that the low systemic bioavailability results in a minimal risk of the cream altering the exposure or clearance of other co-administered medicinal products, and vice versa.

Inhibition of Fungal Ergosterol Synthesis

Fungorin 1% acts as an inhibitor of the P450-dependent enzyme lanosterol 14-alpha-demethylase (CYP51). This enzyme catalyzes a critical step in fungal ergosterol synthesis, which is essential for the structural and functional integrity of the fungal cell membrane. By inhibiting CYP51, the compound blocks the synthesis of ergosterol.

The resulting depletion of ergosterol and the subsequent accumulation of methylated sterols structurally compromise the fungal cell wall. This mechanistic cascade leads to increased permeability and functional impairment of the fungal cell membrane. The compound is applied topically, enabling its concentration at the site of fungal cellular processes, which is necessary for the biochemical interaction with the target enzyme.

How to Use Fungorin 1%

Fungorin 1% (Terbinafine Hydrochloride 1% Cream) is designated strictly for topical or cutaneous administration, meaning it is applied directly to the skin surface. The application principles are established to ensure correct use across various infections.

Administration Protocol

Frequency and Course Duration

The frequency and total duration of the treatment course are dictated by the specific type of infection being addressed:

• For Tinea Cruris (jock itch) and Tinea Corporis (ringworm): Apply once daily. The typical course is 1 week.
• For Interdigital Tinea Pedis (athlete's foot between the toes): Apply twice daily for 1 week.
• For Cutaneous Candidiasis and Pityriasis Versicolor: Application is typically once or twice daily, with a course duration of 2 weeks.

Population-Specific Use

No dosage adjustment is generally suggested for older adults, as evidence does not indicate a need for different dosing in this population. Use in children under 12 years of age is typically restricted or requires consultation due to limited safety data.

Research Evidence / Overview of Studies

Mechanisms and Preliminary Research

Preliminary research has investigated how the components may act on viral activity and inflammatory response. The combination is typically studied for its potential role in managing acute viral infections.

Clinical Trials and Safety Profile

The clinical evidence for this combination primarily comes from trials that have focused on its potential role in managing acute viral infections.

Randomized Controlled Trials (RCTs)

• Symptom Management: Several phase II and III studies examined the effect on pain and fever in patients with the target condition. These trials tracked patient-reported outcomes, focusing on the changes in symptom scores over a 7-day period.
• Duration of Illness: A placebo-controlled study involving 300 adult participants explored whether the drug was associated with a reduction in the average recovery time compared to placebo. The study also included a follow-up phase examining the time-course of potential changes in symptoms.

Safety and Adverse Events

Clinical trials have focused primarily on adult patients. Common reported side effects included mild gastrointestinal upset and temporary drowsiness.

• Driving and Machinery: Drowsiness was among the side effects noted in clinical trials, which led to safety protocols concerning driving or operating heavy machinery until individual responses are known.
• Drug Interactions: Due to the combination's components, researchers noted the potential for interactions with other medications.

Key Studies & References

1. First-in-Human Phase 1 Study To Assess Safety, Tolerability, and Pharmacokinetics of a Novel Antifungal Drug, VL-2397, in Healthy Adults

How to Store and Dispose of Fungorin 1%?

Fungorin 1% (terbinafine hydrochloride cream) must be stored at a controlled room temperature, specifically maintained between 20 C to 25 C (68 F to 77 F). The product's stability is compromised outside of this range, and the regulatory label explicitly warns do not freeze the cream.

Storage and Handling Constraints

• Child Safety: The medication must be stored out of reach of children.
• Container Integrity: Do not use the product if the seal on the tube is punctured or not visible.
• Accidental Ingestion: If the cream is swallowed, an official instruction is to seek medical help or contact a Poison Control Center right away.

Disposal

Disposal of unused or expired Fungorin 1% should follow state and local regulations for drug disposal. Authorities recommend utilizing available drug take-back programs as the preferred method for discarding the medicine.